argenx Shares Rally 2.21% on Surge in 330M Dollar Volume Ranking 305th Amid Autoimmune Pipeline Advances

On September 3, 2025, argenx (ARGX) closed at $721.60, reflecting a 2.21% increase during regular trading hours, despite a -0.06% decline in after-hours trading. The stock saw a trading volume of $0.33 billion, a 36.28% surge from the prior day, ranking 305th in market activity. The biopharma firm’s shares have shown resilience amid ongoing developments in its pipeline targeting autoimmune diseases.

argenx remains focused on advancing therapies for conditions such as generalized myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy. Key programs include efgartigimod for seronegative gMG and thyroid eye disease, as well as ARGX-119 for congenital myasthenic syndromes. Strategic collaborations with partners like AbbVie and Genmab support its R&D efforts. The company’s recent performance aligns with its long-term strategy to expand its commercial-stage portfolio in autoimmune disorders.

Backtesting data for the period shows argenx’s stock rose 2.21% on September 3, with a trading volume of $0.33 billion, up 36.28% from the previous day. The stock closed at $721.60 in regular hours, followed by a -0.06% decline in after-hours trading. These figures reflect immediate market dynamics but do not account for broader sector trends or long-term fundamentals.